Freedom of Information request on possible side effects to the all childhood vaccines in the UK dated from 1975 to present date 2021 please. Aswell as m information on the Yellow card scheme (FOI 22/002)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-17-january-2022/freedom-of-information-request-on-possible-side-effects-to-the-all-childhood-vaccines-in-the-uk-dated-from-1975-to-present-date-2021-please-aswell-as
FOI 22/002
18th January 2022
Dear,
Thank you for your email dated 30th December 2021, where you asked:
“please give me information on side possible side effects to the all childhood vaccines in the UK dated from 1975 to present date 2021 please. Aswel as more information on the Yellow card scheme”
I can confirm that the MHRA collects reports of suspected adverse reactions to medicines and vaccines via the Yellow Card Scheme. The Yellow Card scheme is run by the MHRA and is the UK system for collecting and monitoring information on safety concerns such as suspected side effects or adverse incidents involving medicines and medical devices. The scheme relies on voluntary reporting of suspected side effects or medical device incidents to be reported by health professionals and the public, including patients, carers and parents. Reporting helps others.
The purpose of the scheme is to provide an early warning that the safety of a medicine or a medical device may require further investigation. It is important for people to report problems experienced with medicines or medical devices as these are used to identify issues which might not have been previously known about. The MHRA will review the issue and if necessary, take action to minimise risk and maximise benefit to the patients.
Section 12 of the FOI Act specifies that a public authority may refuse requests where the cost of dealing with them would exceed the appropriate limit, which for central government is set at £600. This represents the estimated cost of one person spending 24 working hours in determining whether the department holds the information, locating, retrieving and extracting the information. We consider that extracting the adverse reactions data that you have requested will take longer than 24 working hours to complete.
We would be able to provide you with Drug Analysis Prints (DAPs) which include the number of reports of all suspected adverse reactions to a particular medicine or vaccine if you were to narrow your request by, for example, limiting your request to specific vaccines on the schedule.
As your request has been refused under Section 12 of the FOI Act, we cannot answer any part of it however we will be happy to provide a response to any refined request you send in the future.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team
Vigilance and Risk Management of Medicines DivisionFOI 22/002
18th January 2022
Dear,
Thank you for your email dated 30th December 2021, where you asked:
“please give me information on side possible side effects to the all childhood vaccines in the UK dated from 1975 to present date 2021 please. Aswel as more information on the Yellow card scheme”
I can confirm that the MHRA collects reports of suspected adverse reactions to medicines and vaccines via the Yellow Card Scheme. The Yellow Card scheme is run by the MHRA and is the UK system for collecting and monitoring information on safety concerns such as suspected side effects or adverse incidents involving medicines and medical devices. The scheme relies on voluntary reporting of suspected side effects or medical device incidents to be reported by health professionals and the public, including patients, carers and parents. Reporting helps others.
The purpose of the scheme is to provide an early warning that the safety of a medicine or a medical device may require further investigation. It is important for people to report problems experienced with medicines or medical devices as these are used to identify issues which might not have been previously known about. The MHRA will review the issue and if necessary, take action to minimise risk and maximise benefit to the patients.
Section 12 of the FOI Act specifies that a public authority may refuse requests where the cost of dealing with them would exceed the appropriate limit, which for central government is set at £600. This represents the estimated cost of one person spending 24 working hours in determining whether the department holds the information, locating, retrieving and extracting the information. We consider that extracting the adverse reactions data that you have requested will take longer than 24 working hours to complete.
We would be able to provide you with Drug Analysis Prints (DAPs) which include the number of reports of all suspected adverse reactions to a particular medicine or vaccine if you were to narrow your request by, for example, limiting your request to specific vaccines on the schedule.
As your request has been refused under Section 12 of the FOI Act, we cannot answer any part of it however we will be happy to provide a response to any refined request you send in the future.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team
Vigilance and Risk Management of Medicines Division